BMJ open · 2025
Serial cardiac magnetic resonance imaging to assess myocardial inflammation in PET-positive cardiac sarcoidosis under immunomodulatory therapy: a retrospective observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Treiber Julia Mareen, Wolter Jan Sebastian, Backhaus Sören J, Siefert Erika Platt, Rieth Andreas, Kriechbaum Steffen D, Klemm Philipp, Tarner Ingo, Mueller-Ladner Ulf, Sossalla Samuel, Rolf Andreas
Аннотация
OBJECTIVE: To evaluate changes in cardiac magnetic resonance (CMR) tissue characteristics in patients with active cardiac sarcoidosis (CS) confirmed by positron emission tomography (PET)-CT undergoing immunomodulatory therapy (IMT), and to explore their potential use for inflammation monitoring.
DESIGN: Retrospective observational cohort study.
SETTING: Tertiary care referral centre in Germany.
PARTICIPANTS: From a cohort of 47 patients with CS, 24 patients with PET-confirmed active myocardial inflammation and complete baseline and follow-up CMR imaging after ≥6 months of IMT were included.
PRIMARY AND SECONDARY ENDPOINTS: Primary outcome: Changes in CMR-derived tissue characteristics (T1, T2 mapping, late gadolinium enhancement (LGE) mass).
SECONDARY OUTCOMES: Changes in functional (ejection fraction (EF) and global longitudinal strain (GLS)) and morphological parameters (end-diastolic/systolic volume indices (EDVi/ESVi)).
RESULTS: Patients with PET-confirmed active CS show increased global T1 and T2 compared with healthy volunteers. Over the course of IMT, significant reductions in global T2 (median (IQR): 39 (38-41) ms vs 37 (36-39) ms; p=0.002), LGE-region T2 (43 (40-46) ms vs 41 (38-42) ms; p=0.003), and relative LGE mass (23% (17-38) vs 15% (8-32); p=0.006) were observed. No significant differences were found in EF (p=0.78), GLS (p=0.49), EDVi (p=0.56), ESVi (p=0.28) or native T1 values (p=0.23).
CONCLUSION: In patients with PET-confirmed active CS undergoing IMT, serial CMR demonstrated measurable changes in T2 mapping and LGE parameters, suggesting a potential role for CMR tissue characterisation in monitoring myocardial inflammation. However, due to the observational design and absence of a control group, causal treatment effects cannot be confirmed. Further prospective studies are needed to validate the utility of CMR for treatment monitoring in CS.
DESIGN: Retrospective observational cohort study.
SETTING: Tertiary care referral centre in Germany.
PARTICIPANTS: From a cohort of 47 patients with CS, 24 patients with PET-confirmed active myocardial inflammation and complete baseline and follow-up CMR imaging after ≥6 months of IMT were included.
PRIMARY AND SECONDARY ENDPOINTS: Primary outcome: Changes in CMR-derived tissue characteristics (T1, T2 mapping, late gadolinium enhancement (LGE) mass).
SECONDARY OUTCOMES: Changes in functional (ejection fraction (EF) and global longitudinal strain (GLS)) and morphological parameters (end-diastolic/systolic volume indices (EDVi/ESVi)).
RESULTS: Patients with PET-confirmed active CS show increased global T1 and T2 compared with healthy volunteers. Over the course of IMT, significant reductions in global T2 (median (IQR): 39 (38-41) ms vs 37 (36-39) ms; p=0.002), LGE-region T2 (43 (40-46) ms vs 41 (38-42) ms; p=0.003), and relative LGE mass (23% (17-38) vs 15% (8-32); p=0.006) were observed. No significant differences were found in EF (p=0.78), GLS (p=0.49), EDVi (p=0.56), ESVi (p=0.28) or native T1 values (p=0.23).
CONCLUSION: In patients with PET-confirmed active CS undergoing IMT, serial CMR demonstrated measurable changes in T2 mapping and LGE parameters, suggesting a potential role for CMR tissue characterisation in monitoring myocardial inflammation. However, due to the observational design and absence of a control group, causal treatment effects cannot be confirmed. Further prospective studies are needed to validate the utility of CMR for treatment monitoring in CS.